The EMA initially rejected Rezurock due to uncertainty over its clinical benefit, noting that the pivotal study had no comparator arm and permitted concomitant therapies.
Medscape News Europe
Source link : https://www.medscape.com/viewarticle/rejected-cgvhd-therapy-gets-second-look-ema-2025a1000vxi?src=rss
Author :
Publish date : 2025-11-17 14:35:00
Copyright for syndicated content belongs to the linked Source.
